Hepatitis B Virus Reactivation 55 Months Following Chemotherapy Including Rituximab and Autologous Peripheral Blood Stem Cell Transplantation for Malignant Lymphoma

A 54-year-old woman underwent chemotherapy including rituximab and autologous peripheral blood stem cell transplantation (auto-PBSCT) for diffuse large B-cell lymphoma. Before the treatment, she exhibited a resolved hepatitis B virus (HBV) infection. She was diagnosed with HBV reactivation based on...

Descripción completa

Detalles Bibliográficos
Autores principales: Hara, Tasuku, Oka, Kohei, Iwai, Naoto, Inada, Yutaka, Tsuji, Toshifumi, Okuda, Takashi, Nagata, Akihiro, Komaki, Toshiyuki, Kagawa, Keizo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Japanese Society of Internal Medicine 2020
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7925277/
https://www.ncbi.nlm.nih.gov/pubmed/32963163
http://dx.doi.org/10.2169/internalmedicine.5678-20
_version_ 1783659246688141312
author Hara, Tasuku
Oka, Kohei
Iwai, Naoto
Inada, Yutaka
Tsuji, Toshifumi
Okuda, Takashi
Nagata, Akihiro
Komaki, Toshiyuki
Kagawa, Keizo
author_facet Hara, Tasuku
Oka, Kohei
Iwai, Naoto
Inada, Yutaka
Tsuji, Toshifumi
Okuda, Takashi
Nagata, Akihiro
Komaki, Toshiyuki
Kagawa, Keizo
author_sort Hara, Tasuku
collection PubMed
description A 54-year-old woman underwent chemotherapy including rituximab and autologous peripheral blood stem cell transplantation (auto-PBSCT) for diffuse large B-cell lymphoma. Before the treatment, she exhibited a resolved hepatitis B virus (HBV) infection. She was diagnosed with HBV reactivation based on positive serum HBV-DNA test results, 55 months after her last treatment. Subsequently, he was treated with tenofovir alafenamide fumarate (TAF) therapy and her liver function improved. Patients undergoing chemotherapy including rituximab and auto-PBSCT are at a high risk of HBV reactivation. In such cases, careful and long-term observations may be required to detect HBV reactivation.
format Online
Article
Text
id pubmed-7925277
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher The Japanese Society of Internal Medicine
record_format MEDLINE/PubMed
spelling pubmed-79252772021-03-10 Hepatitis B Virus Reactivation 55 Months Following Chemotherapy Including Rituximab and Autologous Peripheral Blood Stem Cell Transplantation for Malignant Lymphoma Hara, Tasuku Oka, Kohei Iwai, Naoto Inada, Yutaka Tsuji, Toshifumi Okuda, Takashi Nagata, Akihiro Komaki, Toshiyuki Kagawa, Keizo Intern Med Case Report A 54-year-old woman underwent chemotherapy including rituximab and autologous peripheral blood stem cell transplantation (auto-PBSCT) for diffuse large B-cell lymphoma. Before the treatment, she exhibited a resolved hepatitis B virus (HBV) infection. She was diagnosed with HBV reactivation based on positive serum HBV-DNA test results, 55 months after her last treatment. Subsequently, he was treated with tenofovir alafenamide fumarate (TAF) therapy and her liver function improved. Patients undergoing chemotherapy including rituximab and auto-PBSCT are at a high risk of HBV reactivation. In such cases, careful and long-term observations may be required to detect HBV reactivation. The Japanese Society of Internal Medicine 2020-09-19 2021-02-01 /pmc/articles/PMC7925277/ /pubmed/32963163 http://dx.doi.org/10.2169/internalmedicine.5678-20 Text en Copyright © 2021 by The Japanese Society of Internal Medicine https://creativecommons.org/licenses/by-nc-nd/4.0/ The Internal Medicine is an Open Access journal distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License. To view the details of this license, please visit (https://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Case Report
Hara, Tasuku
Oka, Kohei
Iwai, Naoto
Inada, Yutaka
Tsuji, Toshifumi
Okuda, Takashi
Nagata, Akihiro
Komaki, Toshiyuki
Kagawa, Keizo
Hepatitis B Virus Reactivation 55 Months Following Chemotherapy Including Rituximab and Autologous Peripheral Blood Stem Cell Transplantation for Malignant Lymphoma
title Hepatitis B Virus Reactivation 55 Months Following Chemotherapy Including Rituximab and Autologous Peripheral Blood Stem Cell Transplantation for Malignant Lymphoma
title_full Hepatitis B Virus Reactivation 55 Months Following Chemotherapy Including Rituximab and Autologous Peripheral Blood Stem Cell Transplantation for Malignant Lymphoma
title_fullStr Hepatitis B Virus Reactivation 55 Months Following Chemotherapy Including Rituximab and Autologous Peripheral Blood Stem Cell Transplantation for Malignant Lymphoma
title_full_unstemmed Hepatitis B Virus Reactivation 55 Months Following Chemotherapy Including Rituximab and Autologous Peripheral Blood Stem Cell Transplantation for Malignant Lymphoma
title_short Hepatitis B Virus Reactivation 55 Months Following Chemotherapy Including Rituximab and Autologous Peripheral Blood Stem Cell Transplantation for Malignant Lymphoma
title_sort hepatitis b virus reactivation 55 months following chemotherapy including rituximab and autologous peripheral blood stem cell transplantation for malignant lymphoma
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7925277/
https://www.ncbi.nlm.nih.gov/pubmed/32963163
http://dx.doi.org/10.2169/internalmedicine.5678-20
work_keys_str_mv AT haratasuku hepatitisbvirusreactivation55monthsfollowingchemotherapyincludingrituximabandautologousperipheralbloodstemcelltransplantationformalignantlymphoma
AT okakohei hepatitisbvirusreactivation55monthsfollowingchemotherapyincludingrituximabandautologousperipheralbloodstemcelltransplantationformalignantlymphoma
AT iwainaoto hepatitisbvirusreactivation55monthsfollowingchemotherapyincludingrituximabandautologousperipheralbloodstemcelltransplantationformalignantlymphoma
AT inadayutaka hepatitisbvirusreactivation55monthsfollowingchemotherapyincludingrituximabandautologousperipheralbloodstemcelltransplantationformalignantlymphoma
AT tsujitoshifumi hepatitisbvirusreactivation55monthsfollowingchemotherapyincludingrituximabandautologousperipheralbloodstemcelltransplantationformalignantlymphoma
AT okudatakashi hepatitisbvirusreactivation55monthsfollowingchemotherapyincludingrituximabandautologousperipheralbloodstemcelltransplantationformalignantlymphoma
AT nagataakihiro hepatitisbvirusreactivation55monthsfollowingchemotherapyincludingrituximabandautologousperipheralbloodstemcelltransplantationformalignantlymphoma
AT komakitoshiyuki hepatitisbvirusreactivation55monthsfollowingchemotherapyincludingrituximabandautologousperipheralbloodstemcelltransplantationformalignantlymphoma
AT kagawakeizo hepatitisbvirusreactivation55monthsfollowingchemotherapyincludingrituximabandautologousperipheralbloodstemcelltransplantationformalignantlymphoma

Ejemplares similares